论文部分内容阅读
目的:系统评价康艾注射液联合化疗治疗非小细胞肺癌(NSCLC)的疗效。方法:检索2005-2011年国内发表的康艾注射液联合化疗治疗NSCLC的随机对照试验(RCT),采用Rev Man 5.0对符合条件的文献进行Meta分析。结果:共纳入13项RCT,合计972例患者。Meta分析结果显示,与对照组比较,康艾注射液联合化疗治疗NSCLC的近期疗效较好,RR=1.38,95%CI:1.18～1.61;生存质量改善率较高,RR=1.87,95%CI:1.60～2.19。结论:康艾注射液联合化疗治疗非小细胞肺癌的近期疗效和生存质量改善率方面优于对照组。
Objective: To systematically evaluate the curative effect of Kangai injection combined with chemotherapy in the treatment of non-small cell lung cancer (NSCLC). Methods: A randomized controlled trial (RCT) of Kangai injection combined with chemotherapy in China was conducted in 2005-2011. Meta-analysis was performed on qualified patients using Rev Man 5.0. Results: A total of 13 RCTs were enrolled, totaling 972 patients. The results of Meta analysis showed that Kangai injection combined with chemotherapy had a better short-term curative effect compared with the control group (RR = 1.38, 95% CI: 1.18-1.61), higher quality of life improvement (RR = 1.87, 95% CI : 1.60 ~ 2.19. Conclusion: Kangai injection combined with chemotherapy in the treatment of non-small cell lung cancer in the short term efficacy and quality of life improvement is better than the control group.